Detalhe da pesquisa
1.
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Ann Rheum Dis
; 77(2): 234-240, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29042358
2.
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 76(1): 51-57, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26150601
3.
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 76(1): 58-64, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26318384
4.
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Ann Rheum Dis
; 76(2): 355-363, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27130908
5.
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Rheumatology (Oxford)
; 56(12): 2093-2101, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28968793
6.
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Rheumatology (Oxford)
; 56(10): 1771-1779, 2017 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28957563
7.
Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countries.
Rheumatol Int
; 36(6): 845-54, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26923691
8.
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
Ann Rheum Dis
; 71(4): 541-8, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21994233
9.
[Recommendations for the prevention and management of tuberculosis in patients treated with tumor necrosis factor alpha inhibitors: a consensus of lithuanian pulmonologists and rheumatologists]. / Tuberkuliozes prevencijos ir gydymo rekomendacijos skiriantnaviko nekrozes faktoriaus alfa blokatorius (Lietuvos pulmonologu ir reumatologu sutarimas)
Medicina (Kaunas)
; 47(3): 187-91, 2011.
Artigo
em Lt
| MEDLINE | ID: mdl-21822042
10.
Nurse's Role from Medical Students' Perspective during Their Interprofessional Clinical Practice: Evidence from Lithuania.
Healthcare (Basel)
; 9(8)2021 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34442100
11.
Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.
Ther Adv Musculoskelet Dis
; 13: 1759720X211051471, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34707696
12.
Clinical characteristics and long-term outcomes of 35 patients with Wegener's granulomatosis followed up at two rheumatology centers in Lithuania.
Medicina (Kaunas)
; 46(4): 256-60, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20571293
13.
Severe vancomycin-induced anaphylactic reaction.
Medicina (Kaunas)
; 46(1): 30-3, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20234160
14.
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients.
Drugs Context
; 92020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33123205
15.
The impact of anti-cyclic citrullinated peptide antibody status on the management of patients with early rheumatoid arthritis: observational study results from Lithuania.
Acta Med Litu
; 25(2): 112-123, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30210246
16.
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Arthritis Rheumatol
; 70(1): 40-48, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950421
17.
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Arthritis Rheumatol
; 70(6): 832-840, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439289
18.
An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study.
J Int Med Res
; 45(4): 1417-1429, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28617199
19.
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Arthritis Res Ther
; 18: 82, 2016 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27038608
20.
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.
Arthritis Res Ther
; 11(1): R7, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19144159